Infectious Disease In-Vitro Diagnostic Market - Global Infectious Disease In-Vitro Diagnostic Industry Analysis, Size, Share, Growth, Trends, and Forecast 2025-2032 - (By Product Type, By Technology, By End User, By Geographic Coverage and By Company)

The global market for infectious disease in-vitro diagnostics (IVD) is on track for significant expansion, with its valuation expected to reach US$ 61.2 Bn by 2032, growing from US$ 44.5 Bn in 2025. The market is anticipated to witness a CAGR of 4.7% between 2025 and 2032, driven by technological advancements, rising disease prevalence, and increased investments in healthcare infrastructure.

Market Trends
• The demand for cutting-edge diagnostic solutions is surging due to the rising cases of HIV, tuberculosis, and COVID-19.
• The industry includes essential segments such as instruments, reagents, and software & services, each fulfilling distinct roles.
• Advances in molecular diagnostics, AI-enabled platforms, and point-of-care testing are enhancing efficiency and accessibility.
• Increased funding for disease surveillance, healthcare improvements, and research & development is driving market progression.
• North America is expected to hold a leading market share, attributed to its well-developed healthcare infrastructure, technological innovations, and government initiatives.

Key Growth Drivers

1. Surge in Home Testing and Telemedicine Adoption
Growing preference for self-testing for diseases like HIV, COVID-19, and STIs.
Expansion of telehealth services supports the demand for home-based diagnostic solutions.

2. Breakthroughs in Molecular Diagnostics and Precision Medicine
Technologies such as Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and AI-powered diagnostics are revolutionizing disease detection.
Market leaders are continuously innovating and expanding their diagnostic portfolios.
ELITechGroup is set to introduce advanced molecular diagnostic equipment in Europe by 2024.

Business Growth Opportunities

1. Biosensors Enhancing Companion Diagnostics
Biosensor technology is driving advancements in precision diagnostics for diseases such as HIV, HCV, and COVID-19.
OraSure’s OraQuick® rapid test exemplifies biosensor integration in tailored treatment strategies.

2. Rise of Multiplex Testing for Infectious Agents
Multiplex molecular diagnostics allow simultaneous detection of multiple pathogens in one test.
Notable platforms such as BioFire FilmArray® and GenMark ePlex® are streamlining diagnostic processes for respiratory and gastrointestinal infections.

Regional Market Overview

1. North America: A Hub for Technological Advancements
Dominance of leading companies including Abbott, Roche, and Siemens Healthineers.
Increased government investments in disease prevention and healthcare infrastructure.
Growing adoption of AI-driven diagnostics and molecular testing reinforces North America’s leadership.

2. Asia Pacific: Strengthening Healthcare Investments
WHO reports that 44% of global tuberculosis cases originate from the Asia-Pacific region.
Dengue cases have surged by 30% over the last decade, necessitating improved diagnostic tools.
India’s National Tuberculosis Elimination Program (NTEP) screens 100 million individuals annually.

Major Market Players
• QIAGEN
• Becton, Dickinson and Company
• bioMérieux SA
• Hoffmann-La Roche Ltd.
• Hologic, Inc. (Gen Probe)
• Abbott
• Quidel Corporation
• Siemens Healthineers AG
• Bio-Rad Laboratories, Inc.
• Danaher
• OraSure Technologies, Inc.

Competitive Analysis

Key developments and partnerships in the market include:
• BD acquired Edwards Lifesciences' Critical Care division in September 2024, reinforcing its patient monitoring solutions.
• Roche finalized its acquisition of LumiraDx’s Point of Care technology in July 2024, enhancing its diagnostics portfolio.
• BD and Techcyte formed a strategic alliance in January 2024 to integrate AI-powered digital diagnostics for cervical cancer screening.

Market Outlook
• Advancements in AI, molecular diagnostics, and multiplex testing are transforming the industry.
• Enhanced diagnostic tools will enable faster and more accurate disease detection.
• Emerging regions, with growing disease prevalence and healthcare funding, provide untapped opportunities.
• Government initiatives are expanding healthcare access, supporting technological innovations and market expansion.

Segmentation Overview
• By Product Type: Instruments, Reagents, Software & Services.
• By Technology: Immunoassay, Molecular Diagnostics, Microbiology, Others.
• By Application: MRSA, Clostridium Difficile, Respiratory Virus, TB and Drug-resistant TB, HIV, HPV, Hepatitis B & C, COVID-19, and others.
• By End User: Point-of-care, Central Laboratories, Others.
• By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa.


Please note: Delivery Timelines - 5 working days.